Kintara offers peek at mid-stage data in relapsed glioblastoma patients; Jazz wins quick approval for pediatric cancer drug
Among the dozens of cancer types, glioblastoma has proven one of the hardest to crack with little clinical success over the years. Now, a San Diego biotech is rolling out mid-stage data it claims could be pointing its drug in the right direction in relapsed patients. But there are several caveats.
A high dose of Kintara’s VAL-083 spurred a median OS of 8 months in patients with recurrent glioblastoma who had been previously treated with chemotherapy temozolomide, according to topline data from an open-label Phase II study conducted at MD Anderson Cancer Center in Houston.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.